Cephalon Provigil follow-on clears FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Approved labeling for Cephalon's follow-on compound armodafinil includes a bolded warning that a "serious rash requiring hospitalization and discontinuation of treatment" has been reported in patients using the product. Nuvigil was approved June 15 for excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome, narcolepsy and shift work sleep disorder. The bolded warning adds that Nuvigil is not approved for use by children for any indication. A similar warning will be added to labeling for Cephalon's first-generation product Provigil (modafinil). Rashes were seen in children taking the firm's Sparlon, which also has modafinil as its active ingredient, in studies for a potential attention deficit/hyperactivity disorder indication. Nuvigil had received an "approvable" letter in April 2006, with FDA requesting data on the rashes related to Sparlon (1Pharmaceutical Approvals Monthly May 2006, p. 19)...
You may also be interested in...
Nuvigil Label Likely To Include Safety Information From Sparlon Trials
Final approved labeling for Cephalon’s Nuvigil (armodafinil) will likely include results of an FDA safety review for the firm’s other pending product, attention deficit hyperactivity disorder treatment Sparlon (modafinil).
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.